Comparative analysis of the public health impact of pentavalent and trivalent rotavirus vaccine in China
Introduction: Vaccines continue to play a crucial role in safeguarding the public health by preventing and controlling the spread of infectious diseases. This study aims to compare the public health impact of RotaTeq (which has shown more than seven years duration of protection in previous studies),...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | International Journal of Infectious Diseases |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971224006040 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Introduction: Vaccines continue to play a crucial role in safeguarding the public health by preventing and controlling the spread of infectious diseases. This study aims to compare the public health impact of RotaTeq (which has shown more than seven years duration of protection in previous studies), previously shown to be more effective than the current Lanzhou Lamb Rotavirus (LLR) Vaccine with LLR3, a newly available trivalent vaccine in China. Hence, we sought to understand the public health impact of widespread rotavirus vaccination with these two vaccines on public health outcomes, in China, among children aged 0-7 years old. Methods: A Markov model that follows a cohort from 0 to 7 years of age was developed to simulate the natural history of rotavirus disease. The model was used to evaluate three different scenarios- i) vaccination with RotaTeq; ii) vaccination with LLR3; iii) no-vaccination to estimate the number of rotavirus-related cases. The model was parameterized using published information on rotavirus epidemiology, up-to-date RotaTeq effectiveness and LLR3 efficacy in China, and incidence of 11,996/100,000 among children in China as abstracted from national estimates and the peer-reviewed literature. Based on the natural history of rotavirus disease, the model considered that individuals could have up to five rotavirus infections, the first two being the ones that could lead to hospitalization. Due to limited clinical evidence for the newly available LLR3, two different vaccine waning profiles based on locally existing products (LLR and RotaTeq) were used to estimate the impact of LLR3. We considered high (90%) and low (50%) vaccination coverage scenarios (since rotavirus vaccines are in the private market). Results/Discussion: For a cohort of 100,000 children over the first 7 years of life, and in the absence of a rotavirus vaccine in China, 64,746 symptomatic rotavirus cases, 11,708 outpatient visits and 899 hospitalizations are expected. Using RotaTeq, 86%(49%) of rotavirus symptomatic cases and outpatient visits, and 85%(49%) of hospitalizations can be averted compared to no vaccination under the high(low) vaccination coverage scenario. Using LLR3, under the LLR waning profile assumption, would avert 40%(23%) of rotavirus symptomatic cases and outpatient visits, and 50%(29%) hospitalizations compared to no vaccination, in the high(low) vaccination coverage scenario. Using LLR3 (with assumed RotaTeq waning profile), would avert 48%(28%) of rotavirus symptomatic cases and outpatient visits, and 61%(35%) hospitalizations compared to no vaccination, in the high(low) vaccination coverage scenario. Conclusion: Widespread use of rotavirus vaccines can avert a significant number of RVGE outcomes, with close to two times higher potential public health impact for RotaTeq compared with LLR3. |
|---|---|
| ISSN: | 1201-9712 |